{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T15:26:04Z","timestamp":1793805964646,"version":"4.6.1"},"reference-count":35,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.urolonc.2026.06.006","type":"journal-article","created":{"date-parts":[[2026,6,28]],"date-time":"2026-06-28T06:07:24Z","timestamp":1782626844000},"page":"263-271","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Ipsilateral sampling maintains clinically significant cancer detection and reduces overdiagnosis in PI-RADS 4\u20135 lesions"],"prefix":"10.1016","volume":"44","author":[{"given":"Cassandra","family":"Jeavons","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4733-2577","authenticated-orcid":false,"given":"Kevin","family":"An","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yilin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lea","family":"Lough","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Marcuzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sobhan","family":"Mardan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miles","family":"Mannas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9201-8114","authenticated-orcid":false,"given":"Silvia D.","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.urolonc.2026.06.006_bib0001","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA: Cancer J Clin"},{"issue":"1","key":"10.1016\/j.urolonc.2026.06.006_bib0002","first-page":"45","article-title":"Early detection of prostate cancer: AUA\/SUO guideline part I: prostate cancer screening","volume":"210","author":"Wei","year":"2023","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2026.06.006_bib0003","unstructured":"Cornford P, Tilki D, van den Bergh, RCN et al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer. uroweb.org. Updated April 2024. Accessed June 6, 2024. https:\/\/uroweb.org\/guidelines\/prostate-cancer\/chapter\/diagnostic-evaluation."},{"key":"10.1016\/j.urolonc.2026.06.006_bib0004","unstructured":"PI-RADS\u2122 v2.1. acr.org. Published 2019. Accessed June 6, 2024. https:\/\/www.acr.org\/-\/media\/ACR\/Files\/RADS\/Pi-RADS\/PI-RADS-v2.1.pdf"},{"issue":"1","key":"10.1016\/j.urolonc.2026.06.006_bib0005","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1111\/bju.14017","article-title":"Prospective comparison of transperineal magnetic resonance imaging\/ultrasonography fusion biopsy and transrectal systematic biopsy in biopsy-naive patients","volume":"121","author":"Borkowetz","year":"2018","journal-title":"BJU Int"},{"issue":"1","key":"10.1016\/j.urolonc.2026.06.006_bib0006","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1080\/08941939.2020.1825884","article-title":"Use of prostate systematic and targeted biopsy on the basis of bi-parametric magnetic resonance imaging in biopsy-naive patients","volume":"35","author":"Cheng","year":"2020","journal-title":"J Invest Surg"},{"issue":"6","key":"10.1016\/j.urolonc.2026.06.006_bib0007","doi-asserted-by":"crossref","first-page":"2510","DOI":"10.21037\/tau-20-1001","article-title":"Systematic sampling during MRI-us fusion prostate biopsy can overcome errors of targeting-prospective single center experience after 300 cases in first biopsy setting","volume":"9","author":"Cata","year":"2020","journal-title":"Transl Androl Urol"},{"issue":"6","key":"10.1016\/j.urolonc.2026.06.006_bib0008","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1002\/cncr.29874","article-title":"Prostate cancer detection with magnetic resonance-ultrasound fusion biopsy: the role of systematic and targeted biopsies","volume":"122","author":"Filson","year":"2016","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.urolonc.2026.06.006_bib0009","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1111\/iju.14149","article-title":"Magnetic resonance imaging\/transrectal ultrasonography fusion targeted prostate biopsy finds more significant prostate cancer in biopsy-naive Japanese men compared with the standard biopsy","volume":"27","author":"Fujii","year":"2020","journal-title":"Int J Urol"},{"issue":"10","key":"10.1016\/j.urolonc.2026.06.006_bib0010","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1056\/NEJMoa1910038","article-title":"MRI-targeted, systematic, and combined biopsy for prostate cancer diagnosis","volume":"382","author":"Ahdoot","year":"2020","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.urolonc.2026.06.006_bib0011","doi-asserted-by":"crossref","first-page":"235.e1","DOI":"10.1016\/j.urolonc.2020.12.015","article-title":"Do patients with a PI-RADS 5 lesion identified on magnetic resonance imaging require systematic biopsy in addition to targeted biopsy?","volume":"39","author":"Drobish","year":"2021","journal-title":"Urol Oncol"},{"issue":"2","key":"10.1016\/j.urolonc.2026.06.006_bib0012","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.euo.2021.03.004","article-title":"Using prostate imaging-reporting and data system (PI-RADS) scores to select an optimal prostate biopsy method: a secondary analysis of the trio study","volume":"5","author":"Ahdoot","year":"2022","journal-title":"Eur Urol Oncol"},{"issue":"11","key":"10.1016\/j.urolonc.2026.06.006_bib0013","doi-asserted-by":"crossref","first-page":"7544","DOI":"10.1007\/s00330-022-08822-3","article-title":"Prostate biopsy in the era of MRI-targeting: towards a judicious use of additional systematic biopsy","volume":"32","author":"Deniffel","year":"2022","journal-title":"Eur Radiol"},{"key":"10.1016\/j.urolonc.2026.06.006_bib0014","doi-asserted-by":"crossref","DOI":"10.1007\/s00261-022-03775-z","article-title":"Ipsilateral hemigland prostate biopsy may underestimate cancer burden in patients with unilateral mpMRI-visible lesions","author":"Phelps","year":"2022","journal-title":"Abdom Radiol"},{"key":"10.1016\/j.urolonc.2026.06.006_bib0015","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.urology.2021.05.028","article-title":"Cribriform prostate cancer: clinical pathologic and molecular considerations","volume":"155","author":"Hesterberg","year":"2021","journal-title":"Urology"},{"issue":"17","key":"10.1016\/j.urolonc.2026.06.006_bib0016","doi-asserted-by":"crossref","first-page":"4065","DOI":"10.3390\/cancers14174065","article-title":"The role of perineural invasion in prostate cancer and its prognostic significance","volume":"14","author":"Niu","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.urolonc.2026.06.006_bib0017","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.euo.2018.05.003","article-title":"Extraprostatic extension in core biopsies epitomizes high-risk but locally treatable prostate cancer","volume":"2","author":"Goldberg","year":"2019","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.urolonc.2026.06.006_bib0018","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.euros.2022.07.006","article-title":"An magnetic resonance imaging-directed targeted-plus-perilesional biopsy approach for prostate cancer diagnosis: \"less is more\"","volume":"43","author":"Hagens","year":"2022","journal-title":"Eur Urol Open Sci"},{"issue":"1","key":"10.1016\/j.urolonc.2026.06.006_bib0019","doi-asserted-by":"crossref","first-page":"31","DOI":"10.23736\/S2724-6051.22.05189-8","article-title":"A prospective randomized controlled trial comparing target prostate biopsy alone approach vs. target plus standard in na\u00efve patients with positive mpMRI","volume":"75","author":"Porpiglia","year":"2023","journal-title":"Minerva Urol Nephrol"},{"issue":"4","key":"10.1016\/j.urolonc.2026.06.006_bib0020","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1007\/s00330-011-2377-y","article-title":"ESUR prostate MR guidelines 2012","volume":"22","author":"Barentsz","year":"2012","journal-title":"Eur Radiol"},{"issue":"8","key":"10.1016\/j.urolonc.2026.06.006_bib0021","doi-asserted-by":"crossref","first-page":"e87","DOI":"10.1097\/PAS.0000000000001497","article-title":"The 2019 international society of urological pathology (ISUP) consensus conference on grading of prostatic carcinoma","volume":"44","author":"van Leenders","year":"2020","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.urolonc.2026.06.006_bib0022","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.euros.2022.04.001","article-title":"Diagnostic performance of a magnetic resonance imaging-directed targeted plus regional biopsy approach in prostate cancer diagnosis: a systematic review and meta-analysis","volume":"40","author":"Hagens","year":"2022","journal-title":"Eur Urol Open Sci"},{"key":"10.1016\/j.urolonc.2026.06.006_bib0023","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.euros.2020.06.006","article-title":"Genetic landscape of prostate cancer conspicuity on multiparametric Magnetic resonance imaging: a systematic review and bioinformatic analysis","volume":"20","author":"Norris","year":"2020","journal-title":"Eur Urol Open Sci"},{"issue":"17","key":"10.1016\/j.urolonc.2026.06.006_bib0024","doi-asserted-by":"crossref","first-page":"5612","DOI":"10.3390\/jcm12175612","article-title":"Prostate biopsy in the case of PI-RADS 5-is systematic biopsy mandatory?","volume":"12","author":"Malewski","year":"2023","journal-title":"J Clin Med"},{"key":"10.1016\/j.urolonc.2026.06.006_bib0025","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.euros.2022.01.006","article-title":"There is no longer a role for systematic biopsies in prostate cancer diagnosis","volume":"38","author":"Kasivisvanathan","year":"2022","journal-title":"Eur Urol Open Sci"},{"key":"10.1016\/j.urolonc.2026.06.006_bib0026","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.euros.2024.03.006","article-title":"The impact of omitting contralateral systematic biopsy on the surgical planning of patients with a unilateral suspicious lesion on magnetic resonance imaging undergoing robot-assisted radical prostatectomy for prostate cancer","volume":"63","author":"van den Kroonenberg","year":"2024","journal-title":"Eur Urol Open Sci"},{"issue":"4","key":"10.1016\/j.urolonc.2026.06.006_bib0027","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1038\/s41391-021-00485-3","article-title":"Reducing the number of systematic biopsy cores in the era of MRI targeted biopsy-implications on clinically-significant prostate cancer detection and relevance to focal therapy planning","volume":"25","author":"Lee","year":"2022","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"1","key":"10.1016\/j.urolonc.2026.06.006_bib0028","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1097\/JU.0000000000002963","article-title":"Clinical significance of perineural invasion in men with grade group 1 prostate cancer on active surveillance","volume":"209","author":"de la Calle","year":"2023","journal-title":"J Urol"},{"issue":"23","key":"10.1016\/j.urolonc.2026.06.006_bib0029","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1056\/NEJMoa2209454","article-title":"Prostate cancer screening with PSA and MRI followed by targeted biopsy only","volume":"387","author":"Hugosson","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2026.06.006_bib0030","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.urology.2016.11.017","article-title":"The role of ipsilateral and contralateral transrectal ultrasound-guided systematic prostate biopsy in men with unilateral magnetic resonance imaging lesion undergoing Magnetic resonance imaging-ultrasound fusion-targeted prostate biopsy","volume":"102","author":"Bryk","year":"2017","journal-title":"Urology"},{"issue":"3","key":"10.1016\/j.urolonc.2026.06.006_bib0031","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1001\/jamaoncol.2020.7456","article-title":"Population-based prostate cancer screening with Magnetic resonance imaging or ultrasonography: the IP1-PROSTAGRAM study","volume":"7","author":"Eldred-Evans","year":"2021","journal-title":"JAMA Oncol"},{"issue":"3","key":"10.1016\/j.urolonc.2026.06.006_bib0032","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.euf.2021.03.027","article-title":"Update from the ReIMAGINE prostate cancer screening Study NCT04063566: inviting men for prostate cancer screening using magnetic resonance imaging","volume":"7","author":"Marsden","year":"2021","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.urolonc.2026.06.006_bib0033","article-title":"Prevalence of MRI lesions in men responding to a GP-led invitation for a prostate health check: a prospective cohort study","volume":"2","author":"Moore","year":"2023","journal-title":"BMJ Oncol"},{"issue":"11","key":"10.1016\/j.urolonc.2026.06.006_bib0034","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1002\/pros.24547","article-title":"Stimulated Raman histology, a novel method to allow for rapid pathologic examination of unprocessed, fresh prostate biopsies","volume":"83","author":"Mannas","year":"2023","journal-title":"Prostate"},{"issue":"3","key":"10.1016\/j.urolonc.2026.06.006_bib0035","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1097\/JU.0000000000003811","article-title":"Stimulated Raman histology interpretation by artificial intelligence provides near-real-time pathologic feedback for unprocessed prostate biopsies","volume":"211","author":"Mannas","year":"2024","journal-title":"J Urol"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143926005648?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143926005648?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T14:28:52Z","timestamp":1793802532000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143926005648"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":35,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S1078143926005648"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2026.06.006","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ipsilateral sampling maintains clinically significant cancer detection and reduces overdiagnosis in PI-RADS 4\u20135 lesions","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2026.06.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}